Document is current
Any future updates will be listed below
-
Authors
West, Howard Jack https://orcid.org/0000-0003-3257-0086
McCleland, Mark
Cappuzzo, Federico
Reck, Martin
Mok, Tony SK
Jotte, Robert M
Nishio, Makoto
Kim, Eugene
Morris, Stefanie
Zou, Wei
Shames, David
Das Thakur, Meghna
Shankar, Geetha
Socinski, Mark A
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02366143 at ClinicalTrials.govDocuments that mention this clinical trial
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
1197 Harnessing the cancer immunity cycle via machine learning models to generate novel strategies for personalized cancer therapy
https://doi.org/10.1136/jitc-2024-sitc2024.1197
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in <i>KRAS-</i>mutated non-small cell lung cancer with <i>STK11</i>, <i>KEAP1,</i> or <i>TP53</i> comutations: subgroup results from the phase III IMpower150 trial
https://doi.org/10.1136/jitc-2021-003027
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd./Genentech, Inc.
- License Information
